# Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C

> **NCT00227435** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** val-mCyd

## Key facts

- **NCT ID:** NCT00227435
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** — (—)
- **Last updated:** 2016-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227435, "Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00227435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*